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5-(2-(4-Methoxyphenyl)ethyl)-2-amino-3-methylcarboxylate thiophene (TR560) is the prototype drug
of a recently discovered novel class of tumor-selective compounds that preferentially inhibit the pro-
liferation of speciﬁc tumor cell types (e.g. leukemia/lymphoma). Here, we further increased tumor
selectivity by simpliﬁcation of the molecule through replacing the 4-methoxyphenyl moiety by an alkyl
chain. Several 2-amino-3-methylcarboxylate thiophene derivatives containing at C-5 an alkyl group
consisting of at least 6 (hexyl) to 9 (nonyl) carbon units showed pronounced anti-proliferative activity in
the mid-nanomolar range with 500- to 1000-fold tumor cell selectivity. The compounds preferentially
inhibited the proliferation of T-lymphoma CEM and Molt/4, prostate PC-3, kidney Caki-1 and hepatoma
Huh-7 tumor cells, but were virtually inactive against other tumor cell lines including B-lymphoma Raji
and cervix carcinoma HeLa cells. The novel prototype drug 3j (containing a 5-heptyl chain) elicited a
cytotoxic, rather than cytostatic activity, already after 4 h of exposure. The unusual tumor selectivity
could not be explained by a differential uptake (or efﬂux) of the drug by sensitive versus resistant tumor
cells. Exposure of a ﬂuorescent derivative of 3j revealed pronounced uptake of the drug in the cytoplasm,
no visible appearance in the nucleus, and a predominant localization in the endoplasmic reticulum.
These observations may be helpful to narrow down the intracellular localization and identiﬁcation of the
molecular target of the 5-substituted thiophene derivatives.
© 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ation; THF, tetrahydrofuran;
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Most clinically effective antitumor agents are inhibitors of DNA,
RNA or protein synthesis, or interfere with the metabolism of other
cell components, frequently lacking or displaying poor selective
antitumor activity [1e7]. These traditional antitumor agents often
poorly discriminate between tumor and normal non-tumor cells,
especially those with high proliferative potential. A number of
novel technologies, including antibody-drug conjugates [1],
transporter-related tumor targeting of small anticancer drugs [2],
prodrugs of anticancer agents [3], targeting of agents to deﬁned
(cancer) tissues [4], or speciﬁc delivery systems for anticancer
drugs [5e7], have recently become subject of extensive in-
vestigations to improve anticancer selectivity.
We recently identiﬁed 5-substituted methyl 2-amino-3-
carboxylate thiophenes with anti-proliferative activity against
speciﬁc tumor cell lines [8,9]. The prototype compound (TR560)
contains a methyl 2-amino-3-carboxylate thiophene core linked atarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Structure of 1.5-(2-(4-Methoxyphenyl)ethyl)-2-amino-3-methylcarboxylate
thiophene.
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(i.e. ethyl) linker [8] (Fig. 1). This tumor-speciﬁc compound was
originally synthesised with the aim to design and develop a novel
class of antitumor agents that target tubulin [10]. The most active
derivatives indeed markedly inhibited tubulin assembly and bind-
ing of radiolabeled colchicine to tubulin [10]. Most of the syn-
thesised compounds showed pronounced anti-proliferative activity
against an extensive panel of tumor cell lines, and did not
discriminate between T- and B-cell lymphoma/leukemia, nor be-
tween several types of solid tumors including colon, mammary,
glioma, prostate and osteosarcoma [10]. Instead, TR560 inhibited
the proliferation of several human T-cell (but not B-cell lymphoma
or monocyte-derived tumor cell lines), as well as several solid tu-
mor cell lines derived from prostate (i.e. PC-3), kidney (i.e. Caki-1)
and hepatoma (i.e. Huh-7) (but not colon, mammary, cervix or
glioma). Moreover, the tumor-selective compound(s) showed poor,
if any, anti-tubulin activity, and thus, may have acquired a more
speciﬁc molecular mechanism of action. TR560 inhibited theTable 1
Methyl 2-amino-5-alkylthiophene-3-carboxylate derivatives.
Entry Compound code R1
1 3a -CH3
2 3b -CH2CH3
3 3c -(CH2)2CH3
4 3d -(CH2)3CH3
5 3e -(CH2)4OH
6 3f -(CH2)4CH3
7 3g -CH2CH]CHCH2CH3
8 3h -(CH2)5CH3
9 3i -(CH2)6OH
10 3j -(CH2)6CH3
11 3k -(CH2)7OH
12 3l -(CH2)3CH¼CHCH2CH3
13 3m -(CH2)6-C6H5
14 3n -(CH2)7CH3
15 3o -CH(CH3)CH2CH2CH¼C(C
16 3p -(CH2)7CH¼CH2
17 3q -(CH2)7CH¼CH2
18 3r -(CH2)7CH3
19 3s -(CH2)8CH3
20 3t -(CH2)7CXCH
21 3u -(CH2)6CXC-CH3
22 3v -(CH2)9CH3
23 3w -(CH2)9CH2OH
24 3x -(CH2)10CH3
25 3y -(CH2)11CH3
26 3z -(CH2)12CH3
27 3aa -(CH2)13CH3
28 3ab -(CH2)8CH¼CH(CH2)3CH
29 3ac -(CH2)14CH3
30 3ad -(CH2)15CH3proliferation of the sensitive tumor cell lines in the high nanomolar
range while being poorly active against several other tumor cell
lines (IC50 values in the mid-micromolar range). As a result, 60-fold
tumor selectivity for T-cell lymphoma tumor cells compared to
HeLa cells was obtained [8]. A slight increase in tumor selectivity
could be achieved by further exploring and optimizing the sub-
stituents on the 5-phenylethyl group of the methyl 2-amino-3-
carboxylate thiophene molecule [9]. In the current study, we
investigated whether tumor selectivity could be further increased
by replacing the 5-phenyl moiety by a methyl 2-amino-3-
carboxylate thiophene thereby creating a symmetrical molecule,
or by simply deleting the aromatic phenyl moiety and introducing
structural variability in the aliphatic alkyl linker chain. We
demonstrate that simpliﬁcation of the prototype drug structure of
TR560 to 5-alkyl-substituted methyl 2-amino-3-carboxylate thio-
phenes resulted in a substantial increase of anti-proliferative po-
tency and markedly enhanced tumor selectivity (500- and 1400-
fold for T-cell lymphoma versus B-cell lymphoma Raji and cervical
carcinoma HeLa cells, respectively).2. Results
2.1. Chemistry
The Gewald three-component reaction, which results in the
formation of a compound containing a multisubstituted 2-R2 R3 Yield
H COOMe 33%
H COOMe 41%
H COOMe 53%
H COOMe 72%
H COOMe 56%
H COOMe 77%
H COOMe 86%
H COOMe 85%
H COOMe 83%
H COOMe 79%
H COOMe 78%
H COOMe 82%
H COOMe 56%
H COOMe 89%
H3)2 H COOMe 73%
H CN 3%
H COOMe 85%
CH3 COOMe 6%
H COOMe 92%
H COOMe 27%
H COOMe 85%
H COOMe 93%
H COOMe 76%
H COOMe 85%
H COOMe 91%
H COOMe 89%
H COOMe 94%
3 H COOMe 90%
H COOMe 91%
H COOMe 94%
Scheme 1. Synthesis of 2-amino-5-(7-aminoheptyl)thiophene derivative 6.
Scheme 2. Miscellaneous derivatives of 2-amino-3-carboxymethylthiophene.
Table 2
Methyl 2-amino-5-((alkylthio)methyl)thiophene-3-carboxylate derivatives.
Entry Compound code R Yield
1 10a -(CH2)3CH3 33%
2 10b -(CH2)4CH3 39%
3 10c -(CH2)2CH(CH3)2 36%
4 10d -(CH2)5CH3 43%
5 10e -(CH2)6CH3 39%
6 10f -(CH2)7CH3 47%
7 10g -(CH2)9CH3 49%
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the 3-position has been widely applied for the synthesis and dis-
covery of large libraries of potentially bioactive molecules [11,12].
This reaction generally involves an intermolecular Knoevenagel
condensation reaction with an enolizable aldehyde and an acti-
vated nitrile followed by a base-promoted reaction with elemental
sulfur followed by ring closure. The synthetic methodology applied
for the preparation of the target compounds 3a-3ad is shown in
Table 1 based upon this reaction. Thus, condensation of various
saturated and unsaturated aliphatic aldehydes with the methyl
cyanoacetate in the presence of elemental sulfur and triethylamineTable 3
Bis-methyl 2-amino-5-alkylthiophene-3-carboxylate derivatives.
Entry Compound code
1 12a
2 12b
3 12c
4 12dyielded alkyl-2-aminothiophene-3-carboxylate derivatives 3a-3o,
3q and 3s-3ad in good to excellent yields. Similarly, aminonitrile
derivative 3p was prepared by replacing methyl cyanoacetate with
a malonitrile building block whereas 3-methyl aminothiophene
derivative 3r was obtained by using the corresponding ketone,
decan-2-one, instead of the aldehyde derivative. However, the
yields of the last two reactions were very low as compared to the
other reactions.
A multi-step procedure was followed for the synthesis of 2-
amino-5-(7-aminoheptyl)thiophene derivative 6. This reaction at
ﬁrst involved the synthesis of phthalimido derivative 5 in goodn Yield
2 33%
4 42%
5 53%
8 44%
Scheme 3. Synthesis of ﬂuorescent derivatives of 6.
Table 4
Tumor cell selectivity of 5-alkylthiophene-substituted methyl 2-amino-3-carboxylate thiophene derivatives.
SH2N
H3COOC
S(CH2)n NH2
COOCH3
Code n IC50a (mM) Ratio IC50b
Lymphoma tumor cells Carcinoma tumor cells Raji/CEM HeLa/PC-3
CEM Molt/4 Raji PC-3 Huh-7 Caki-1 HeLa
12a 2 5e100 65 ± 19 174 ± 6 11 ± 9 25 ± 3 41 ± 21 >100 2e35 >9
12b 4 2.4 ± 0.2 1.1 ± 0.2 83 ± 0 2.9 ± 3.6 64 ± 15 34 ± 28 52 ± 8 35 18
12c 5 0.46 ± 0.01 0.57 ± 0.51 83 ± 3 0.49 ± 0.27 25 ± 0 9.8 ± 0.5 48 ± 17 180 98
12d 8 0.76 ± 0.48 0.18 ± 0.05 58 ± 23 1.5 ± 0.4 2.4 ± 0.8 4.7 ± 2.5 50 ± 9 76 33
Prototype 1 0.90 ± 0.43 0.27 ± 0.08 57 ± 16 0.19 ± 0.04 0.95 ± 0.21 1.7 ± 1.1 39 ± 11 63 205
a 50%-inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%.
b Ratio of the IC50 values obtained for drug-insensitive Raji versus drug-sensitive CEM, or drug-insensitive HeLa versus drug-sensitive PC-3 tumor cells.
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group by using hydrazine hydrate in reﬂuxing ethanol over a period
of 12 h (Scheme 1).
Next, we synthesized a series of compounds by replacing the
ethylene spacer between the alkyl chain and the 2-aminothiophene
of the prototype compound 3 by a thiomethylene bridge. This re-
action involved the classical nucleophilic substitution reactionwith
various alkyl thiols and phthalimido derivative 8 [9] in the presence
of K2CO3 as base in THF over a period of 24 h which furnished
phthaloyl-protected intermediates 9a-g in good yields. The desired
compounds 10a-g were obtained by the removal of the phthaloyl
group by use of hydrazine hydrate in reﬂuxing ethanol over a
period of 12 h (Table 2).
An extension of the Gewald-multicomponent reaction where a
double Gewald reaction was performed on a bifunctional building
block such as enolizable bis-aliphatic aldehydes resulted in the
synthesis of bis-2-aminothiophene derivatives 12a-12d in reason-
able yields (Table 3). As expected, a slightly longer reaction time is
required for this reaction.
An analogue of compound 10where the sulfur atomwas directly
connected at the 5-position of 2-aminothiophene moiety 15
was synthesized by utilizing an efﬁcient Pd(OAc)2/1,1'-bis(diisopropylphosphino)ferrocene-catalyzed cross-coupling re-
action (Scheme 2). In order to investigate the signiﬁcance of
extending the ethylene spacer to an unsaturated group, the Sono-
gashira cross-coupling reaction has been employed on to the 5-
bromo derivative of protected 2-aminothiophene 13 [10]. These
reactions delivered the expected compounds 14a and 14b after the
removal of the protecting group (Scheme 2).
Finally, ﬂuorescent derivatives of 6 such as its dansyl derivative
17 and 7-nitrobenzofurazan derivative 19were also synthesized by
using the classical base-mediated reactions as shown in Scheme 3.
2.2. Biology
2.2.1. Structure-activity relationship of the methyl 2-amino-3-
carboxylate thiophene derivatives
The prototype compound TR560 containing a methyl 2-amino-
3-carboxylate thiophene core linked at its C-5 position to a 4-
methoxy-substituted phenyl ring through an ethylene linker
showed preferential anti-proliferative activity against T-cell leu-
kemia/lymphoma compared to B-cell lymphoma cells [8]. The
compound also inhibited the proliferation of several solid tumor
cell lines, such as prostate PC-3, hepatomaHuh-7 and kidney Caki-1
J. Thomas et al. / European Journal of Medicinal Chemistry 132 (2017) 219e235 223without affecting cervix carcinoma HeLa cells [8,9]. Earlier studies
revealed the crucial importance of an intact methyl 2-amino-3-
carboxylate thiophene entity in the drug molecule to preserve
anti-proliferative activity [8,9]. We now sought to further explore
the structure-activity relationship of 5-phenylalkyl-methyl 2-
amino-3-carboxylate thiophenes in which the substituted phenyl
group was replaced by a methyl 2-amino-3-carboxylate thiophene
entity, or methyl 2-amino-3-carboxylate thiophenes containing a
simple (un)substituted aliphatic alkyl/alkenyl/alkynyl/thioalkyl
chain at the C-5 position.
Given the importance of the methyl 2-amino-3-carboxylate
thiophene core to preserve the anti-proliferative activity [8,9],
symmetrical molecules were designed containing two methyl 2-
amino-3-carboxylate thiophenes linked by an alkyl group with
variable length (Table 4). When replacing the 4-methoxyphenyl
group by a methyl 2-amino-3-carboxylate thiophene keeping the
original ethylene linker moiety (12a), a substantial decrease in anti-
proliferative activity was observed against the tumor cell lines
tested. However, expanding the ethyl to a butyl linker (12b)
markedly increased the anti-proliferative activity, in particular in T-Table 5
Tumor cell selectivity of 5-alkyl-substituted methyl 2-amino-3-carboxylate thiophenes.
SR1 NH2
COOCH3
Code R1 IC50a (mM)
Lymphoma tumor cells
CEM Molt/4 Raji
3a -CH3 250 26 ± 1 >250
3b -CH2CH3 175 ± 18 29 ± 5 >250
3c -(CH2)2CH3 6.9 ± 2.4 2.1 ± 0.5 104 ± 3
3d -(CH2)3CH3 4.6 ± 1.4 0.90 ± 0.26 113 ± 4
3e -(CH2)4OH 58 ± 24 30 ± 0 >250
3f -(CH2)4CH3 0.98 ± 0.09 0.13 ± 0.03 106 ± 0
3g -CH2CH]CHCH2CH3 4.4 ± 1.4 1.1 ± 0.0 113 ± 7
3h -(CH2)5CH3 0.20 ± 0.12 0.033 ± 0.019 113 ± 4
3i -(CH2)6OH 0.19 ± 0.01 1.4 ± 0.2 116 ± 1
3j -(CH2)6CH3 0.18 ± 0.08 0.057 ± 0.026 105 ± 2
14a -C^C-(CH2)4CH3 0.39 ± 0.06 e e
3k -(CH2)7OH 0.074 ± 0.001 0.18 ± 0.00 109 ± 5
6 -(CH2)7NH2 1.7 ± 1.3 0.80 ± 0.10 69 ± 1
3l -(CH2)3CH¼CHCH2CH3 0.25 ± 0.04 0.15 ± 0.02 99 ± 13
3m -(CH2)6-C6H5 0.47 ± 0.14 0.15 ± 0.03 112 ± 2
3n -(CH2)7CH3 0.27 ± 0.19 0.096 ± 0.031 102 ± 5
3o -CH2(CH3)CH2CH2CH¼C(CH3)2 13 ± 5 2.3 ± 1.7 116 ± 8
3pc -(CH2)7CH¼CH2 0.19 ± 0.09 0.11 ± 0.03 5.7 ± 2.
3q -(CH2)7CH¼CH2 0.28 ± 0.10 0.62 ± 0.16 >250
3rd -(CH2)7CH3 16 ± 0 5.7 ± 1.6 125 ± 1
3s -(CH2)8CH3 0.18 ± 0.04 0.058 ± 0.019 95 ± 38
3t -(CH2)7C^CH 0.15 ± 0.02 0.10 ± 0.02 87 ± 14
3u -(CH2)6C^C-CH3 0.16 ± 0.09 0.070 ± 0.049 74 ± 14
3v -(CH2)9CH3 0.33 ± 0.20 0.17 ± 0.02 97 ± 10
3w -(CH2)9CH2OH 0.16 ± 0.04 0.079 ± 0.048 86 ± 7
3x -(CH2)10CH3 0.46 ± 0.01 0.76 ± 0.05 115 ± 2
14b -C^C-C6H5-(CH2)5CH3 0.36 ± 0.03 e e
3y -(CH2)11CH3 0.56 ± 0.09 0.14 ± 0.03 109 ± 1
3z -(CH2)12CH3 1.3 ± 0.0 0.78 ± 0.02 >250
3aa -(CH2)13CH3 1.0 ± 0.3 - -
3ab -(CH2)8CH¼CH(CH2)3CH3 0.22 ± 0.02 0.082 ± 0.035 98 ± 17
3ac -(CH2)14CH3 6.1 ± 3.9 25 ± 17 >250
3ad -(CH2)15CH3 6.4 ± 1.7 5.3 ± 0.8 >250
Prototype -(CH2)2(4-(CH3O)C6H5 0.90 ± 0.43 0.27 ± 0.08 57 ± 16
a 50%-inhibitory concentration or compound concentration required to inhibit tumor
b Ratio of the IC50 values obtained for drug-insensitive Raji versus drug-sensitive CEM
c Compound 3q contains a cyano (-C^N) group instead of carboxymethyl at the C-3 p
d Compound 3s contains a methyl (-CH3) group at the C-4 position of the thiophene rlymphoma CEM and Molt/4 and in prostate cancer PC-3 cells
(Table 4). Further extension of the linker to a pentyl (12c) or an
octyl (12d) chain fully restored the initial tumor selectivity of the
prototype compound for most tumor cell lines tested, while
maintaining the anti-proliferative activity observed for TR560
(Table 4).
To reveal the importance of the second methyl 2-amino-3-
carboxylate thiophene in the increased anti-proliferative activity
of the symmetrical compounds, a large series of methyl 2-amino-3-
carboxylate thiophene derivatives containing unsubstituted alkyl
chains at the C-5 position of the thiophene ring were synthesized.
Whereas the shortest methyl (3a) and ethyl (3b) substituents at C-5
did not result in relevant anti-proliferative activity, the propyl and
butyl derivatives 3c and 3d were inhibitory in the low micromolar
range (Table 5). Higher alkyl derivatives (i.e. pentyl to nonyl) (viz.
3f, 3h, 3j, 3n and 3s) were invariably inhibitory to all sensitive
tumor cell lines at nanomolar concentrations. Longer alkyl chains
(i.e. decyl to hexadecyl) (viz. 3v, 3x, 3y, 3z, 3aa, 3ab, 3ac and 3ad)
showed a progressively lower anti-proliferative potency. Such a
clear structure-anti-proliferative activity relationship was evidentRatio IC50b
Carcinoma tumor cells Raji/CEM HeLa/PC-3
PC-3 Huh-7 Caki-1 HeLa
9.7 ± 6.3 94 ± 53 29 ± 8 >250 >1< 26
27 ± 1 84 ± 23 92 ± 11 180 ± 98 >1.4 6.7
3.4 ± 1.5 2.5 ± 0.5 5.4 ± 2.9 61 ± 1 16 18
4.5 ± 0.5 2.0 ± 1.2 5.6 ± 5.0 77 ± 2 25 17
7.0 ± 5.9 45 ± 15 61 ± 52 >100 >4 >4
0.63 ± 0.04 0.68 ± 0.15 1.4 ± 0.7 83 ± 13 108 132
2.5 ± 1.1 5.8 ± 1.6 15 ± 5 94 ± 10 28 38
0.43 ± 0.03 0.37 ± 0.09 0.57 ± 0.05 73 ± 27 565 170
3 0.98 ± 0.59 22 ± 7 10 ± 4 >100 611 >102
0 0.62 ± 0.09 0.34 ± 0.09 0.54 ± 0.37 81 ± 1 583 131
0.42 ± 0.29 1.0 ± 0.0 1.3 ± 0.6 100 e 238
0.54 ± 0.35 7.0 ± 1.9 2.6 ± 0.6 100 1473 185
10 ± 3 43 ± 26 12 ± 9 85 ± 9 41 8.5
0.39 ± 0.21 0.63 ± 0.55 1.4 ± 0.5 88 ± 8 396 225
5 1.2 ± 0.0 0.95 ± 0.19 1.2 ± 0.7 65 ± 3 238 54
0.71 ± 0.09 0.16 ± 0.07 0.64 ± 0.03 86 ± 15 378 121
17 ± 12 9.8 ± 4.2 26 ± 14 97 ± 2 8.9 5.7
4 0.22 ± 0.00 0.19 ± 0.05 0.34 ± 0.03 21 ± 5 30 95
1.3 ± 0.7 0.74 ± 0.17 1.8 ± 1.6 60 ± 10 >893 46
25 ± 0 46 ± 10 43 ± 7 84 ± 10 7.8 3.4
0.65 ± 0.17 0.71 ± 0.41 1.2 ± 0.7 161 ± 125 528 248
0.30 ± 0.16 0.32 ± 0.23 0.55 ± 0.06 86 ± 16 580 287
0.22 ± 0.07 0.21 ± 0.12 0.40 ± 0.02 60 ± 39 463 273
1.2 ± 0.0 1.4 ± 0.4 3.8 ± 2.2 68 ± 27 294 57
0.32 ± 0.10 1.7 ± 0.2 3.7 ± 2.7 43 ± 18 537 134
2 0.54 ± 0.30 1.2 ± 0.1 0.91 ± 0.27 >100 250 >185
1.5 ± 0.4 1.7 ± 0.0 4.1 ± 2.1 39 ± 1 e 30
9 1.4 ± 0.4 1.3 ± 0.0 2.4 ± 1.7 187 ± 85 195 134
3.7 ± 0.3 4.3 ± 0.8 5.5 ± 4.4 250 >192 68
1.1 ± 0.0 - - >250 >250 >227
0.63 ± 0.02 0.47 ± 0.12 0.92 ± 0.53 55 ± 8 445 87
10 ± 1 40 ± 24 37 ± 32 250 >41 25
4.8 ± 0.2 20 ± 9 3.3 ± 3.2 >250 >39 >52
0.19 ± 0.04 0.95 ± 0.21 1.7 ± 1.1 39 ± 11 63 205
cell proliferation by 50%.
, or drug-insensitive HeLa versus drug-sensitive PC-3 tumor cells.
osition of the thiophene ring.
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Fig. 2. Anti-proliferative activity of 5-alkyl-substituted 2-amino-3-methylcarboxylate thiophene derivatives against human T-lymphoma CEM and prostate PC-3 tumor cells.
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(Fig. 2).
None of the 5-alkyl-substituted methyl 2-amino-3-carboxylate
thiophenes were inhibitory against B-lymphoma Raji or cervix
carcinoma HeLa cell lines, indicating a tumor selectivity proﬁle
similar to the original prototype compound. In this respect, the
tumor selectivity of the most potent 5-alkyl-methyl 2-amino-3-
carboxylate thiophene inhibitors (containing 5 to 9 methylene
units) ranged between 108 and 580when comparing IC50 values for
T-lymphocyte CEM versus B-lymphomas Raji cells, or between 132
and 248when comparing IC50 values for prostate PC-3 versus cervix
carcinoma cells HeLa (Table 5).
Introduction of an unsaturated alkyl chain (i.e. 3g, 3l, 3m, 3r, 3u,
3w, 3ad) did not improve the anti-proliferative activity. Function-
alization of the alkyl chain by an end-standing hydroxyl (3e, 3i, 3k,
3w) or amino (i.e. 6) group resulted in variable anti-proliferative
activities, i.e. decreased activity of 3e and 3i compared to the cor-
responding unsubstituted alkyl derivatives, but equal or slightly
superior anti-proliferative activity of 3k and 3w, depending on the
tumor cell line tested (Table 5).Table 6
Tumor cell selectivity of 5-alkylthiomethyl-substituted methyl 2-amino-3-carboxylate th
SR1 NH2
COOCH3
Code R1 IC50a (mM)
Lymphoma tumor cells
CEM Molt/4 Raji
10a -(CH2S)(CH2)3CH3 0.52 ± 0.37 0.23 ± 0.08 112 ± 1
10b -(CH2S)(CH2)4CH3 0.83 ± 0.28 0.19 ± 0.00 116 ± 6
10c -(CH2S)(CH2)2CH(CH3)2 0.91 ± 0.33 0.51 ± 0.36 132 ± 4
10d -(CH2S)(CH2)5CH3 7.5 ± 3.8 1.8 ± 0.9 250
10e -(CH2S)(CH2)6CH3 1.5 ± 0.0 0.29 ± 0.17 105 ± 10
10f -(CH2S)(CH2)7CH3 2.9 ± 0.3 2.5 ± 0.1 120 ± 4
10g -(CH2S)(CH2)9CH3 0.70 ± 0.04 0.22 ± 0.07 104 ± 17
15 -(SCH2)(CH2)6CH3 1.0 ± 0.2 0.30 ± 0.01 131 ± 5
Prototype -(CH2)2(4-(CH3O)C6H5 0.90 ± 0.43 0.27 ± 0.08 57 ± 16
a 50%-inhibitory concentration or compound concentration required to inhibit tumor
b Ratio of the IC50 values obtained for drug-insensitive Raji versus drug-sensitive CEMFinally, given the improved potency and tumor selectivity of 5-
alkyl derivatives and our previous ﬁndings, which demonstrated
that the ethylene linker between the methyl 2-amino-3-
carboxylate thiophene and the phenyl in the prototype com-
pound could be replaced by a methylthioether entity [9], a variety
of 5-alkylthiomethyl-substituted methyl 2-amino-3-carboxylate
thiophene derivatives were synthesized (Table 6). The novel
thioether-alkyl derivatives showed a similar tumor selectivity
proﬁle as their corresponding alkyl derivatives. However, theywere
endowed with comparable or inferior anti-proliferative potency
compared to the 5-alkyl derivatives, resulting in lower tumor
selectivity indices.
2.2.2. Anti-proliferative activity and selectivity of compound 3j
Based on its anti-proliferative potency and selectivity in 7 tumor
cell lines (see higher), compound 3j was chosen as the novel pro-
totype drug for further biological studies. First, 3j was evaluated in
the NCI-60 anticancer screen of the US National Institutes of Health
(NIH), containing 60 well-characterized tumor cell lines of different
origins (Fig. 3). 3j inhibited the growth of 15 cancer cell lines atiophene derivatives.
Ratio IC50b
Carcinoma tumor cells Raji/CEM HeLa/PC-3
PC-3 Huh-7 Caki-1 HeLa
0.47 ± 0.26 0.40 ± 0.02 1.5 ± 0.3 81 ± 5 215 172
0.94 ± 0.18 1.3 ± 0.9 3.1 ± 1.5 73 ± 11 140 78
0.84 ± 0.15 0.86 ± 0.03 2.0 ± 0.3 71 ± 46 145 85
19 ± 2 10 ± 6 100 250 33 13
3.5 ± 0.9 3.2 ± 2.2 11 ± 7 71 ± 13 70 20
10 ± 5 20 ± 9 36 ± 28 >100 41 3.4
2.9 ± 1.6 3.0 ± 1.8 3.1 ± 1.3 40 ± 9 149 14
1.5 ± 0.7 3.5 ± 0.1 1.6 ± 0.2 100 131 67
0.19 ± 0.04 0.95 ± 0.21 1.7 ± 1.1 39 ± 11 63 205
cell proliferation by 50%.
, or drug-insensitive HeLa versus drug-sensitive PC-3 tumor cells.
Fig. 3. Anti-proliferative activity of 3j against a broad variety of tumor cell lines. Growth curves and drug response obtained from the NCI-60 screen (NIH).
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phoma cell lines, nanomolar anti-proliferative activity (and even
cytotoxicity at 100 mM)was also detected in several renal, liver, CNS
and prostate cancer cell lines. The NCI-60 screen also revealed a
comparable tumor selectivity of 3j and the initial prototype com-
pound TR560 [8]. Finally, the selectivity proﬁle of 3j was not
comparable to that of any known antitumor drug present in the NIH
database, pointing to a likely novel molecular mechanism of action
of 3j.
We also found a high correlation (r-value between 0.85 and
0.89) between the IC50 values of 30 analogues of this class of
compounds against T-lymphoma CEM and Molt, CEM and solid
prostate PC-3, PC-3 and hepatoma Huh-7 and PC-3 and kidney
Caki-1 tumor cell lines (Suppl. Fig. 1, panels AeD). These ﬁndings
again argue for a similar molecular mechanism of action of the test
compounds against the sensitive lymphoma and solid tumor cell
types included in the study.2.2.3. Cell growth kinetics
The IC50 values depicted in Tables 4e6 were calculated from the
growth curves of the tumor cells as depicted in Fig. 4. Compound 3j
dose-dependently inhibited CEM (panel A) and PC-3 (panel B) tu-
mor cell proliferation, whereas neglectable inhibitory activity was
noted in HeLa cell cultures (panel C). Under these standard exper-
imental conditions, the compound was present at a ﬁxedconcentration for the whole incubation period. Similar growth
curves were found for the original prototype TR560, albeit at
somewhat higher concentrations compared with 3j (Suppl. Fig. 2,
panels AeC).
Next, compound 3jwas administered to PC3 prostate cancer cell
cultures for limited time periods. When exposed for 4, 2 or 1 h
every day at 10 mM for up to ﬁve consecutive days, 3j completely
suppressed PC-3 proliferation upon 4 h-drug exposure, and affor-
ded >80% and >70% suppression upon 2 h- or 1 h-drug exposure
times, respectively. Also, at 2 mM 3j (partially) suppressed tumor
cell proliferation when measured at 5 days after the start of the
experiment (Fig. 4, panel D). Such drug exposure schedule may
somewhat mimic daily drug administration in vivo.
In conclusion, the tumor cell culture kinetic experiments
revealed that the drug does not have to be present continuously to
afford a sustainable tumor cell suppression.2.2.4. Drug resistance selection
As already mentioned above, the identical tumor cell selectivity
of the original prototype TR560 derivative and the novel prototype
compound 3j is strongly suggestive for a similar mechanism of
action. To further demonstrate this, CEM and PC-3 cell cultures
were exposed to escalating concentrations of TR560 or 3j over time,
starting at a ~ 2-fold IC50 drug value, until 10 mM-concentrations
were reached (Fig. 5A). After 40 to 46 subcultivations (3e4 days for
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Fig. 4. Growth curves of CEM (panel A), PC-3 (panel B) and HeLa (panel C) cells in the presence of 3j. Panel D: Effect of daily short 3j-exposure times to PC-3 tumor cell cultures.
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escalating TR560 or 3j concentrations became highly resistant to
their selecting drug, with high cross-resistance to TR560, 3j and 3k
(the closely related and potent 7-hydroxy derivative of 3j) (IC50: 34
to > 50 mM) (Fig. 5B and C).
2.2.5. Uptake and intracellular localization of tumor-sensitive
thiophene derivatives
The molecular basis for the tumor selectivity of TR560 and 3j is
currently still unknown. To exclude differential uptake of the drugs
by sensitive versus resistant tumor cell lines as an underlying
mechanism of tumor selectivity, ﬂuorescent derivatives of 3j, con-
taining a dansyl (compound 17) or a 7-nitrobenzofurazan (NBD)
moiety linked to the alkyl end of 3j through an amine bond
(compound 19) were synthesized. Both compounds showed similar
tumor selectivity properties as the parental prototype 3j. Com-
pound 19 was virtually equally potent in inhibiting CEM cell pro-
liferation as 3j (IC50: 0.58 mM), 17 was somewhat less inhibitory
(IC50: 1 mM). However, both ﬂuorescent compounds were markedly
more inhibitory to CEM and PC-3 cells than to HeLa cells (IC50:
>40 mM) and thus, still kept pronounced tumor cell selectivity
(Table 7). Moreover, both ﬂuorescent compounds showed cross-
reactivity with the 3j- and 19-resistant cells. These observations
indicate that uptake and intracellular localization experiments
carried out with the ﬂuorescent drugs are reliable and relevant for
their non-ﬂuorescent prototype congeners.In a ﬁrst set of uptake experiments drug-sensitive (wild-type)
CEM and PC-3 and naturally drug-resistant HeLa tumor cell cul-
tures were exposed to 17. In all cases, the ﬂuorescent drug was
efﬁciently taken-up and quickly appeared in the cytoplasm of CEM
(panels A, B), PC-3 (panels C, D) and HeLa cells (panels E, F),
excluding preferential uptake of the drug by the sensitive tumor
cells as an underlying mechanism to explain tumor selectivity. No
ﬂuorescence was detected in the nucleus of the tumor cells (Fig. 6),
even after prolonged incubation times (not shown).
In a second set of experiments, intracellular localization of 3j
was investigated using an NBD-carrying ﬂuorescent derivative (19).
This different ﬂuorescent label was introduced to rule out the
possibility that localization of the drug was affected by the ﬂuo-
rescent dansyl moiety as such. Moreover, the NBD label can be
excited with visible light (but not UV light as required for dansyl
excitation) avoiding cross-excitation of red ﬂuorescent protein (see
below). We focused on PC-3 cells for these studies since the cyto-
plasmic area of monolayer cells is much higher than that of sus-
pension (CEM) cells. Alike the dansyl derivative 17, the NBD
ﬂuorescent derivative 19 was abundantly taken-up into the PC-3
cytoplasm but not into the nuclear compartment.
We then exposed PC-3 cell cultures transfected with constructs
expressing red ﬂuorescent protein (RFP) conjugated to an organel-
speciﬁc targeting signal, to 19, and evaluated the localization of the
red and the green signal (Fig. 7). Green ﬂuorescence of 19 clearly
did not colocalize with RFP targeted to the golgi (panels AeC),
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Fig. 5. Upper panels: Drug resistance selection of CEM and PC-3 cell cultures upon dose-escalating exposure to TR560 or 3j. Middle panels: Growth curve of wild-type and drug-
resistant PC-3 cell cultures in the presence of TR560, 3j and 3k. Lower panels: Growth curve of wild-type and drug-resistant. CEM cell cultures in the presence of TR560, 3j and 3k.
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endosomes (panels JeL). While a limited overlap with RFP targeted
to the mitochondria was observed (panels MeO), localization of 19
seemed to overlap to a signiﬁcant extent, but not entirely, with the
endoplasmic reticulum (ER) (panels PeR). Also, a rather sharp
green lining around the nucleus was visible in most 19-treatedTable 7
Anti-proliferative activity of ﬂuorescent 17 and 19 against tumor cells.
Tumor cell lines
IC50a (mM)
CEM PC-3 CEM/TJ191 HeLa
17 1.0 ± 0.2 4.7 ± 1.8 7.7 ± 1.1 47 ± 7
19 0.58 ± 0.01 1.6 ± 0.0 18 ± 4 57 ± 31
3j 0.18 ± 0.08 0.62 ± 0.09 52 ± 3 81 ± 1
a 50% Inhibitory concentration or compound concentration required to inhibit
tumor cell proliferation by 50%.cells, pointing to its presence in, or immediately around, the nu-
clear membrane. Similar localization of the compound was
observed in 3j-resistant PC-3 cell cultures (Suppl. Fig. 3). These
observations implicate that tumor cells that acquired resistance to
the drugs by long-term exposure to escalating drug levels do not
alter their drug uptake (inﬂux) or efﬂux, as also observed earlier for
the naturally drug-resistant HeLa cells.3. Discussion
Structure-activity relationship (SAR) studies revealed that the
tumor-selective prototype drug 5-(2-(4-methoxyphenyl)ethyl)-2-
amino-3-methylcarboxylate thiophene TR560 can be structurally
simpliﬁed to 5-alkyl-substituted methyl 2-amino-3-carboxylate
thiophenes thereby markedly increasing both the cytostatic po-
tency and tumor selectivity (i.e. 3j). Such 5-alkyl-thiophene de-
rivatives have never been reported as anticancer agents, and the
Fig. 6. Exposure of CEM, PC-3 and HeLa tumor cells to ﬂuorescent 16. Panels A (CEM), B (PC-3) and C (HeLa): ﬂuorescence images. Panels D (CEM), E (PC-3) and F (HeLa): merged
pictures of ﬂuorescence- and brightﬁeld images.
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lines is quite unusual and intriguing. Moreover, unlike most cyto-
static/cytotoxic drugs, 3j did not show any toxicity in normal cells,
including normal human ﬁbroblasts (HEL; human embryonic lung
ﬁbroblasts) or blood cells (PBMC, human peripheral blood mono-
nuclear cells) (IC50 > 50 mM, not shown). Evaluation of 3j in the NCI-
60 human tumor cell line panel revealed a unique tumor selectivity
pattern, which was similar to that of the original prototype TR560
[8], but did not resemble any of the compounds included in the NCI
database. This indicates that the response pattern of 3j is unique
and that the compound most likely interacts with a novel drug
target. Although the 5-alkyl-2-amino-3-methylcarboxylate thio-
phenes contain a PAINS (Pan-Assay Interference substructure) that
might affect the activity of a wide variety of proteins, thereby
generating false signals across a variety of assays, and might
potentially generate misleading results [15,16], it is unlikely that
the data generated here are due to aspeciﬁc effects of the mole-
cules. In fact, the compounds from which these new analogues
originate target tubulin and are anti-proliferative agents that do not
discriminate between different types of tumor cells [10]. Instead,
the new 5-substituted 2-amino-3-methylcarboxylate thiophene
derivatives do not target tubulin and showed a signiﬁcant selec-
tivity among a wide variety of tumor cell lines (Fig. 3). Such
selectivity amounted up to 500- to 1500-fold for the best com-
pounds of the series. Also, by varying the length of the 5-alkyl side
chain, a close SAR could be deﬁned for both the highly sensitive T-
lymphoma (CEM) and prostate (PC-3) tumor cell lines, resulting in
optimal anti-proliferative activity for an alkyl chain length between
hexyl and nonyl, and markedly decreasing activities at shorter andlonger alkyl side chains, pointing to a high degree of selectivity and
interaction with a well-deﬁned target. Also, although compounds
with cytostatic/toxic properties were frequently shown in the past
to inhibit virus replication (due to the underlying cellular toxicity,
rather than a speciﬁc antiviral effect), the most active compounds
did not show any measurable antiviral activity when evaluated
against a broad panel of DNA and RNA viruses in at least ﬁve
different cellular assaymodels (not shown). These observations and
the above mentioned properties of the compounds let us to believe
that they do not behave as PAINS. Altogether, 3j showed cytotox-
icity in almost one third of all tested cancer cell lines with over 600-
fold selectivity, i.e. IC50 (50% inhibitory activity) of ~100 nM in
sensitive tumor cell lines versus ~ 60 mM in insensitive tumor cell
lines.
A tight correlation (r-value ranging between 0.85 and 0.89) was
found between the anti-proliferative potencies of around 30
different 5-alkyl-methyl 2-amino-3-carboxylate thiophenes in T-
cell lymphoma CEM versus Molt/4, CEM versus PC-3 prostate, and
PC-3 versus kidney Caki-1 and Huh-7 hepatoma tumor cells. This
suggests that the molecular target of the test compounds in leu-
kemia/lymphoma and solid tumor cell lines is identical
(Suppl. Fig. 1).
Although the molecular mechanism of action is currently un-
known and subject of further studies, the ﬂuorescently labeled
thiophene derivatives were rapidly taken-up by both sensitive
(CEM, PC-3) and insensitive (HeLa) tumor cells. Thus, insensitivity
cannot be explained by a differential cellular drug uptake by the
sensitive versus resistant tumor cells. Interestingly, no measurable
ﬂuorescent signal could be detected in the nucleus of both sensitive
Fig. 7. Subcellular localization of organelle-targeted RFP (red) and ﬂuorescent 3j derivative 19 (green) in wild-type PC-3 cells. Panels AeC: A, Golgi RFP staining; B, 19 (10 mM); C,
merged ﬂuorescence overlaid brightﬁeld image. Panels DeF: D, lysosomes RFP staining; E, 19 (10 mM); F, merged ﬂuorescence overlaid brightﬁeld image. Panels GeI: G, early
endosomes RFP staining; H, 19 (10 mM); I, merged ﬂuorescence overlaid brightﬁeld image. Panels JeL: J, late endosomes RFP staining; K, 19 (10 mM); L, merged ﬂuorescence overlaid
brightﬁeld image. Panels MeO: M, mitochondria RFP staining; N, 19 (10 mM); O, merged ﬂuorescence overlaid brightﬁeld image. Panels PeR: P, endoplasmatic reticulum RFP
staining; Q, 19 (10 mM); R, merged ﬂuorescence overlaid brightﬁeld image.
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present around the nucleus and in the cytoplasm. It is therefore
tempting to conclude that the eventual molecular target of the
novel thiophene drugs is located outside the nucleus, excluding a
wide variety of nuclear proteins and factors as potential targets.
Whereas speciﬁc association/accumulation of the drug could also
be excluded for a number of organelles (i.e. early and late endo-
somes, golgi, lysosomes, …), substantial colocalization within the
ER could be observed. These observations will help to exclude/
conﬁrm intracellular targets for these thiophene derivatives.
4. Conclusions
We identiﬁed a novel class of cytostatic/toxic agents with potent
selectivity against selected tumor cell types. However, in-
vestigations using the NCI-60 screen and our in-house tumor cell
lines revealed that for the different organ-speciﬁc tumor cell clas-
ses, leukemia/lymphoma tumor cells display the highest chance of
sensitivity to the compounds.
The molecular mechanism of tumor cell inhibition is currently
unknown, but a ﬂuorescently-labeled prototype drug revealed a
fast and abundant intracellular uptake by both sensitive and
resistant tumor cell lines without measurable appearance in the
nuclear compartment, most likely excluding a nuclear target for
these compounds.
Once the mechanism of action has been revealed and the
intracellular target identiﬁed, these thiophene derivatives may
qualify for a so-called tailor-made cancer drug application, to be
used solely in patients who suffer from a cancer that expresses this
particular molecular target. Moreover, it may be expected that, due
to their inherent tumor selectivity and poor inhibitory activity
against non-tumorigenic cells, these compounds will be less asso-
ciated with systemic toxic side-effects than traditional chemo-
therapeutics. Indeed, in this respect, the new class of substituted 2-
aminothiophenes differs from traditional chemotherapeutic treat-
ment modalities that are often not selective in their antitumor
activity and also affect normal cells in the tumor-bearing host.
Priority should now be given to reveal the molecular target of
the compounds. This can be performed by CRISPR/Cas technology
or thermal shift assay [17,18]. This will allow optimization of the
lead compounds and will be helpful to better discriminate between
sensitive and non-sensitive tumors.
5. Experimental section
5.1. Chemistry
5.1.1. General experimental methods
NMR spectra were acquired on commercial instruments (Bruker
Avance 300 MHz, Bruker AMX 400 MHz or Bruker Avance IIþ
600 MHz) and chemical shifts (d) are reported in parts per million
(ppm) referenced to tetramethylsilane (1H), or the internal (NMR)
solvent signal (13C). Exact mass measurements were acquired on a
Kratos MS50TC instrument (performed in the EI mode at a reso-
lution of 10,000) or a Bruker Daltonics Apex2 FT-ICR instrument
(performed in the ESI mode at a resolution of 60,000). IR spectra
were recorded on a Bruker-Alpha T FTIR spectrometer with uni-
versal sampling module. Melting points (not corrected) were
determined using a Reichert Thermovar apparatus. For column
chromatography 70e230 mesh silica 60 (E. M. Merck) was used as
the stationary phase. Chemicals received from commercial sources
were used without further puriﬁcation. Reaction solvents were
used as received from commercial sources. The compounds purity
have been estimated by HPLC. The determination of purity was
conducted on a Shimadzu LC-10AT vp system with Prevail C18column (4.6 mm  250 mm, 5 mm). Elution was performed with a
gradient of water/acetonitrile ata ratio of 50/50 for 20 min and
staying at 100% acetonitrile for another 20 min. The ﬂow rate was
1 ml/min. Peaks were detected at 254 nm. The peaks below
retention time of 2.0 min and at 6.30 minwere invariably observed
in each of the chromotograms and is considered as an artifact but is
not related to the synthesized compounds.
5.1.2. Synthesis
5.1.2.1. General procedure for the synthesis of 2-amino-5-
alkylthiophene-3-carboxylate derivatives 3 as shown in Table 1.
A solution of aliphatic carbonyl compound 1 (2 mmol), activated
nitrile (2 mol), elemental sulfur (2 mmol) and triethylamine
(2 mmol) in MeOH (15 ml) was heated at reﬂux temperature for
12 h under argon atmosphere. The MeOH was evaporated under
reduced pressure and the residue was extracted with dichloro-
methane (3  50ml). The combined organic phases were washed
with a saturated solution of NaHCO3, dried over magnesium sulfate
and the solvent was evaporated under reduced pressure. Puriﬁca-
tion by column chromatography (silica, eluent CH2Cl2) afforded 3 as
an off-white solid or a semi-solid.
5.1.2.2. Methyl 2-amino-5-ethylthiophene-3-carboxylate (3b) [13].
Off-white solid (41%, 154 mg); m. p. 46e47 C; 1H NMR (300 MHz,
CDCl3) d 6.62 (s, 1H), 5.82 (s, 2H), 3.79 (s, 3H), 2.60 (dd, J ¼ 7.5,
0.9 Hz, 2H), 1.22 (t, J ¼ 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3)
d 165.87, 161.47, 128.65, 120.59, 106.01, 50.99, 23.11, 15.42; Peak:
96.13%; HRMS (ESIþ): m/z calcd for C8H11NO2S [MþH]þ: 186.0583,
found 186.0587.
5.1.2.3. Methyl 2-amino-5-propylthiophene-3-carboxylate (3c).
Off-white solid (53%, 212 mg); m. p. 40e41 C; 1H NMR (300 MHz,
CDCl3) d 6.61 (s, 1H), 5.71 (s, 2H), 3.79 (s, 3H), 2.55 (t, J¼ 7.4 Hz, 2H),
1.68e1.51 (m, 2H), 0.94 (t, J¼ 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3)
d 165.87, 161.52, 126.93, 121.52, 106.09, 51.01, 31.86, 24.37, 13.64;
HRMS (ESIþ): m/z calcd for C9H13NO2S [MþH]þ: 200.0739, found
200.0733.
5.1.2.4. Methyl 2-amino-5-butylthiophene-3-carboxylate (3d) [14].
Off-white solid (72%, 308 mg); m. p. 47e48 C; 1H NMR (300 MHz,
CDCl3) d 6.61 (s, 1H), 5.80 (s, 2H), 3.79 (s, 3H), 2.57 (t, J¼ 7.1 Hz, 2H),
1.65e1.47 (m, 2H), 1.47e1.27 (m, 2H), 0.91 (t, J ¼ 7.3 Hz, 3H); 13C
NMR (75 MHz, CDCl3) d 165.88, 161.49, 127.17, 121.38, 106.08, 51.00,
33.25, 29.48, 22.13, 13.92; Peak: 99.89%; HRMS (ESIþ):m/z calcd for
C10H15NO2S [MþH]þ: 214.0896, found 214.0899.
5.1.2.5. Methyl 2-amino-5-(4-hydroxybutyl)thiophene-3-carboxylate
(3e). Off-white solid (56%, 256 mg); m. p. 50e51 C; 1H NMR
(300 MHz, CDCl3) d 6.62 (s, 1H), 5.70 (s, 1H), 3.78 (s, 2H), 3.65 (t,
J ¼ 5.9 Hz, 2H), 2.61 (t, J ¼ 6.6 Hz, 1H), 1.75e1.50 (m, 3H); 13C NMR
(75MHz, CDCl3) d 165.84,161.64,126.45,121.69,105.97, 62.65, 51.01,
32.00, 29.52, 27.27; Peak: 99.67%; HRMS (ESIþ): m/z calcd for
C10H15NO3S [MþH]þ: 230.0845, found 230.0841.
5.1.2.6. Methyl 2-amino-5-pentylthiophene-3-carboxylate (3f) [14].
Off-white solid (77%, 350 mg); m. p. 49e50 C; 1H NMR (300 MHz,
CDCl3) d 6.61 (s, 1H), 5.80 (s, 2H), 3.79 (s, 3H), 2.56 (t, J¼ 7.1 Hz, 2H),
1.70e1.48 (m, 2H),1.43e1.22 (m, 4H), 0.89 (t, J¼ 6.7 Hz, 3H); Purity:
96.90%; HRMS (ESIþ): m/z calcd for C11H17NO2S [MþH]þ: 228.1052,
found 228.1053.
5.1.2.7. Methyl (Z)-2-amino-5-(pent-2-en-1-yl)thiophene-3-
carboxylate (3g). Off-white solid (86%, 388 mg); m. p. 47e48 C;
1H NMR (300 MHz, CDCl3) d 6.62 (s, 1H), 5.88 (s, 2H), 5.58e5.39 (m,
2H), 3.77 (s, 3H), 3.31 (d, J ¼ 6.0 Hz, 2H), 2.30e1.94 (m, 2H), 0.99 (t,
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126.06, 125.40, 121.49, 105.97, 50.95, 27.43, 20.56, 14.28; Purity:
95.21%; HRMS (ESIþ):m/z calcd for C11H15NO2S [MþH]þ: 226.0896,
found 226.0891.
5.1.2.8. Methyl 2-amino-5-hexylthiophene-3-carboxylate (3h).
Off-white solid (85%, 410 mg); m. p. 49e50 C; 1H NMR (300 MHz,
CDCl3) d 6.60 (s, 1H), 5.79 (s, 2H), 3.78 (s, 3H), 2.56 (t, J¼ 7.2 Hz, 2H),
1.70e1.47 (m, 2H), 1.47e1.16 (m, 6H), 0.88 (t, J ¼ 5.9 Hz, 3H); 13C
NMR (75MHz, CDCl3) d 165.88, 161.49, 127.23, 121.36, 106.08, 50.99,
31.68, 31.12, 29.82, 28.74, 22.69,14.20; Purity: 96.23%; HRMS (ESIþ):
m/z calcd for C12H19NO2S [MþH]þ: 242.1209, found 242.1201.
5.1.2.9. Methyl 2-amino-5-(6-hydroxyhexyl)thiophene-3-carboxylate
(3i). Off-white solid (73%, 376 mg); m. p. 46e47 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.64 (s, 2H), 3.78 (s, 3H), 3.63 (t,
J¼ 6.4 Hz, 2H), 2.57 (t, J¼ 7.3 Hz, 2H),1.54e1.57 (s, 4H),1.35e1.39 (s,
4H); 13C NMR (75 MHz, CDCl3) d 165.86, 161.56, 126.91, 121.44,
105.97, 63.00, 51.01, 32.71, 31.02, 29.69, 28.75, 25.56; Purity:
96.23%; HRMS (ESIþ): m/z calcd for C12H19NO3S [MþH]þ: 258.1158,
found 258.1156.
5.1.2.10. Methyl 2-amino-5-heptylthiophene-3-carboxylate (3j).
Off-white solid (79%, 404 mg); m. p. 44e45 C; IR (ATR): 3425,
3309, 3167, 2925, 2850, 1655, 1500, 1445, 1257, 1191, 1129, 993, 776,
752; 1H NMR (300 MHz, CDCl3) d 6.60 (s, 1H), 5.79 (s, 2H), 3.78 (s,
3H), 2.56 (t, J ¼ 7.4 Hz, 2H), 1.74e1.39 (m, 2H), 1.44e1.16 (m, 8H),
0.88 (t, J ¼ 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.87, 161.49,
127.22, 121.34, 106.05, 50.99, 31.87, 31.15, 29.81, 29.14, 29.02, 22.76,
14.21; Purity: 95.67%; HRMS (ESIþ): m/z calcd for C13H21NO2S
[MþH]þ: 256.1365, found 256.1669.
5.1.2.11. Methyl 2-amino-5-(7-hydroxyheptyl)thiophene-3-
carboxylate (3k). Off-white solid (78%, 424 mg); m. p. 80e81 C;
IR (ATR): 3447, 3412, 3286, 3183, 2925, 2849, 1659, 1603, 1502,
1444, 1391, 1356, 1253, 1186, 1095, 1068, 1037, 854, 779; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.76 (s, 2H), 3.78 (s, 3H), 3.63 (t,
J ¼ 6.4 Hz, 2H), 2.56 (t, J ¼ 7.3 Hz, 2H), 1.56 (s, 4H), 1.34 (s, 6H); 13C
NMR (75 MHz, CDCl3) d 165.84, 161.59, 126.93, 121.35,105.87, 62.99,
50.97, 32.76, 30.97, 29.71, 29.18, 28.91, 25.70; Purity: 97.74%; HRMS
(ESIþ):m/z calcd for C13H21NO3S [MþH]þ: 272.1314, found 272.1317.
For 1H NMR and 13C NMR spectra, see also Suppl. Fig. 4.
5.1.2.12. Methyl (Z)-2-amino-5-(hept-4-en-1-yl)thiophene-3-
carboxylate (3l). Off-white solid (82%, 416 mg); m. p. 46e47 C;
1H NMR (300 MHz, CDCl3) d 6.61 (s, 1H), 5.85 (s, 1H), 5.88e5.00 (m,
1H), 3.78 (s,1H), 2.57 (t, J¼ 7.5 Hz,1H), 2.23e1.90 (m,1H),1.76e1.45
(m, 1H), 0.95 (t, J ¼ 7.5 Hz, 1H); 13C NMR (75 MHz, CDCl3) d 165.82,
161.60, 132.48, 128.26, 126.64, 121.51, 105.90, 50.93, 31.04, 29.22,
26.37, 20.63, 14.41; Purity: 97.13%; HRMS (ESIþ): m/z calcd for
C13H19NO2S [MþH]þ: 254.1209, found 254.1211.
5.1.2.13. Methyl 2-amino-5-(6-phenylhexyl)thiophene-3-carboxylate
(3m). Off-white solid (56%, 128 mg); m. p. 72e73 C; 1H NMR
(300MHz, CDCl3) d 7.40e7.08 (m, 5H), 6.60 (s, 1H), 5.78 (s, 2H), 3.78
(s, 3H), 2.69e2.50 (m, 4H), 1.765e1.55 (m, 4H), 1.39e1.30 (m, 4H);
13C NMR (75 MHz, CDCl3) d 165.85, 161.48, 142.86, 128.51, 128.35,
127.06,125.71,121.41,106.06, 51.00, 36.02, 31.47, 31.03, 29.78, 29.09,
28.87; Purity: 99.18%; HRMS (ESIþ): m/z calcd for C18H23NO2S
[MþH]þ: 318.1522, found 318.1529.
5.1.2.14. Methyl 2-amino-5-octylthiophene-3-carboxylate (3n).
Off-white solid (89%, 480 mg); m. p. 45e46 C; 1H NMR (300 MHz,
CDCl3) d 6.56 (s, 1H), 5.74 (s, 2H), 3.75 (s, 3H), 2.51 (s, 2H), 1.51 (s,
2H), 1.25e1.20 (m, 10H), 0.83 (s, 3H); 13C NMR (75 MHz, CDCl3)d 165.88, 161.48, 127.24, 121.36, 106.09, 50.99, 31.98, 31.15, 29.82,
29.44, 29.33, 29.07, 22.79, 14.22; Purity: 100%; HRMS (ESIþ): m/z
calcd for C14H23NO2S [MþH]þ: 270.1522, found 270.1523.
5.1.2.15. Methyl 2-amino-5-(6-methylhept-5-en-2-yl)thiophene-3-
carboxylate (3o). Off-white solid (73%, 392 mg); m. p. 49e50 C;
1H NMR (300 MHz, CDCl3) d 6.62 (s, 1H), 5.80 (s, 2H), 5.08 (t,
J ¼ 7.1 Hz, 1H), 3.79 (s, 3H), 2.94e2.81 (m, 2H), 2.82e2.72 (m, 1H),
1.96 (q, J ¼ 7.4 Hz, 2H), 1.68 (s, 3H), 1.60e1.52 (m, 4H), 1.22 (d,
J ¼ 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 169.55, 165.93, 164.89,
161.27, 136.84, 135.59, 133.22, 131.94, 127.80, 124.18, 123.84, 120.22,
109.55, 105.90, 81.21, 80.79, 80.37, 54.58, 50.97, 42.34, 38.73, 38.50,
29.52, 26.26, 25.90, 25.83, 22.63, 21.47, 17.84; Purity: 96.70%; HRMS
(ESIþ): m/z calcd for C14H21NO2S [MþH]þ: 268.1365, found
268.1359.
5.1.2.16. 2-Amino-5-(non-8-en-1-yl)thiophene-3-carbonitrile (3p).
Off-white solid (3%, 15 mg); m. p. 42e43 C; 1H NMR (300 MHz,
CDCl3) d 6.36 (s, 1H), 5.88e5.73 (m, 1H), 5.03e4.90 (m, 2H), 4.62 (s,
2H), 2.58 (t, J ¼ 7.4 Hz, 2H), 2.08e1.98 (m, 2H), 1.65e1.50 (m, 2H),
1.42e1.22 (m, 8H); 13C NMR (75 MHz, CDCl3) d 160.72, 139.24,
130.97, 121.19, 115.83, 114.36, 87.56, 33.88, 31.09, 29.78, 29.24,
29.09, 28.97, 28.92;; HRMS (ESIþ):m/z calcd for C14H20N2S [MþH]þ:
249.1419, found 249.1422.
5.1.2.17. Methyl 2-amino-5-(non-8-en-1-yl)thiophene-3-carboxylate
(3q). Off-white solid (85%, 479 mg); m. p. 38e39 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.88e5.74 (m, 3H), 505e4.90 (m,
2H), 3.78 (s, 3H), 2.56 (t, J ¼ 7.4 Hz, 2H), 2.04 (q, J ¼ 6.8 Hz, 2H),
1.66e1.48 (m, 2H), 1.40e1.25 (s, 8H); 13C NMR (75 MHz, CDCl3)
d 95.87, 91.48, 69.30, 57.19, 51.42, 44.31, 36.14, 19.00, 36.09,
38.87, 40.19, 40.69, 40.86, 40.99; Purity: 97.69%; HRMS
(ESIþ): m/z calcd for C15H23NO2S [MþH]þ: 282.1522, found
282.1527.
5.1.2.18. Methyl 2-amino-4-methyl-5-octylthiophene-3-carboxylate
(3r). Off-white solid (6%, 34 mg); m. p. 40e41 C 1H NMR
(300 MHz, CDCl3) d 5.91 (s, 1H), 3.78 (s, 3H), 2.53 (t, J ¼ 7.5 Hz, 2H),
2.16 (s, 3H), 1.52e1.45 (m, 2H), 1.35e1.23 (m, 10H), 0.89 (s, 3H); 13C
NMR (75 MHz, CDCl3) d 166.68, 161.41, 141.80, 129.86, 120.50, 50.75,
31.99, 31.42, 29.51, 29.38, 29.18, 27.16, 22.78, 14.89, 14.22. HRMS
(ESIþ): m/z calcd for C15H25NO2S [MþH]þ: 284.1678, found
284.1671.
. (3s). Off-white solid (92%, 522 mg); m. p.56e57 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.80 (s, 2H), 3.78 (s, 3H), 2.56 (t,
J ¼ 7.4 Hz, 2H), 1.60e1.41 (m, 2H), 1.36e1.20 (m, 12H), 0.88 (t,
J ¼ 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.88, 161.48, 127.24,
121.36, 106.08, 50.99, 32.01, 31.15, 29.82, 29.63, 29.48, 29.43, 29.06,
22.80, 14.24; Purity: 96.95%; HRMS (ESIþ): m/z calcd for
C15H25NO2S [MþH]þ: 284.1678, found 284.1678.
5.1.2.19. Methyl 2-amino-5-(non-8-yn-1-yl)thiophene-3-carboxylate
(3t). Off-white solid (27%, 150 mg); m. p. 46e47 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.81 (s, 2H), 3.78 (s, 3H), 2.56 (t,
J ¼ 7.1 Hz, 2H), 2.18 (td, J ¼ 7.0, 2.6 Hz, 2H), 1.94 (t, J ¼ 2.6 Hz, 1H),
1.62e1.45 (m, 4H), 1.45e1.23 (m, 6H); 13C NMR (75 MHz, CDCl3)
d 165.84, 161.49, 127.02, 121.40, 106.02, 84.82, 68.26, 50.99, 31.04,
29.75, 28.90, 28.85, 28.71, 28.51,18.47; Purity: 96.11%; HRMS (ESIþ):
m/z calcd for C15H21NO2S [MþH]þ: 280.1365, found 280.1367.
5.1.2.20. Methyl 2-amino-5-(non-7-yn-1-yl)thiophene-3-carboxylate
(3u). Off-white solid (85%, 476 mg); m. p. 42e43 C; 1H NMR
(300 MHz, CDCl3) d 6.59 (s, 1H), 5.79 (s, 2H), 3.77 (s, 3H), 2.56 (t,
J ¼ 7.5 Hz, 3H), 2.10 (t, J ¼ 6.9 Hz, 2H), 1.77 (t, J ¼ 2.5 Hz, 3H),
1.68e1.49 (m, 2H), 1.49e1.26 (m, 6H); 13C NMR (75 MHz, CDCl3)
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29.76, 29.04, 28.67, 28.57, 18.82, 3.61; Purity: 100%; HRMS (ESIþ):
m/z calcd for C15H21NO2S [MþH]þ: 280.1365, found 280.1368.
5.1.2.21. Methyl 2-amino-5-decylthiophene-3-carboxylate (3v).
Off-white solid (93%, 550 mg); m. p. 42e43 C; 1H NMR (300 MHz,
CDCl3) d 6.60 (s, 1H), 5.78 (s, 2H), 3.79 (s, 3H), 2.56 (t, J¼ 7.5 Hz, 2H),
1.63e1.50 (m, 2H), 1.26 (s, 14H), 0.88 (t, J ¼ 6.6 Hz, 3H); 13C NMR
(75MHz, CDCl3) d 165.89,161.46,127.29,121.38,106.15, 51.02, 32.04,
31.17, 29.84, 29.73, 29.68, 29.49, 29.46, 29.08, 22.83, 14.26; Purity:
95.26%; HRMS (ESIþ):m/z calcd for C16H27NO2S [MþH]þ: 298.1835,
found 298.1833.
5.1.2.22. Methyl 2-amino-5-(10-hydroxydecyl)thiophene-3-
carboxylate (3w). Semi-solid (76%, 477 mg); 1H NMR (300 MHz,
CDCl3) d 6.60 (s,1H), 5.85 (s, 2H), 3.78 (s, 3H), 3.63 (t, J¼ 6.6 Hz, 2H),
2.56 (t, J ¼ 7.4 Hz, 2H), 1.63e1.50 (m, 4H), 1.28 (s, 12H); 13C NMR
(75MHz, CDCl3) d 165.85, 161.55, 127.10, 121.33, 105.93, 63.11, 50.98,
32.86, 31.07, 29.77, 29.61, 29.50, 29.37, 28.95, 25.82; Purity: 99.17;
HRMS (ESIþ): m/z calcd for C16H27NO3S [MþH]þ: 314.1784, found
314.1789.
5.1.2.23. Methyl 2-amino-5-undecylthiophene-3-carboxylate (3x).
Off-white solid (85%, 530 mg); m. p. 36e37 C; 1H NMR (300 MHz,
CDCl3) d 6.77 (s, 1H), 5.72 (s, 2H), 3.78 (s, 3H), 2.56 (t, J¼ 7.4 Hz, 2H),
1.66e1.50 (m, 2H), 1.40e1.18 (s, 16H), 0.88 (t, J ¼ 6.7 Hz, 3H); 13C
NMR (75 MHz, CDCl3) d 165.89, 161.48, 127.26, 121.36, 106.10, 51.01,
32.05, 31.16, 29.83, 29.7 29.76, 29.68, 29.48, 29.08, 22.83, 14.26;
Purity: 99.77%; HRMS (ESIþ): m/z calcd for C17H29NO2S [MþH]þ:
312.1991, found 312.1987.
5.1.2.24. Methyl 2-amino-5-dodecylthiophene-3-carboxylate (3y).
Off-white solid (91%, 591 mg); m. p. 50e51 C; 1H NMR (300 MHz,
CDCl3) d 6.60 (s, 1H), 5.78 (s, 2H), 3.78 (s, 3H), 2.56 (t, J¼ 7.1 Hz, 2H),
1.61e1.53 (m, 2H), 1.40e1.22 (m, 18H), 0.89 (t, J ¼ 8.8, 4.7 Hz, 3H);
13C NMR (75 MHz, CDCl3) d 165.89, 161.47, 127.27, 121.37, 106.12,
51.01, 32.06, 31.17, 29.84, 29.80, 29.78, 29.68, 29.49, 29.08, 22.83,
14.26; Purity: 96.81%; HRMS (ESIþ): m/z calcd for C18H31NO2S
[MþH]þ: 326.2148, found 326.2141.
5.1.2.25. Methyl 2-amino-5-tridecylthiophene-3-carboxylate (3z).
Off-white solid (89%, 605 mg); m. p. 60e61 C; 1H NMR (300 MHz,
CDCl3) d 6.60 (s, 1H), 5.74 (s, 2H), 3.78 (s, 3H), 2.56 (t, J¼ 7.2 Hz, 2H),
1.70e1.45 (m, 2H), 1.38e1.20 (s, 20H), 0.88 (t, J ¼ 6.6 Hz, 3H); 13C
NMR (75 MHz, CDCl3) d 165.89, 161.48, 127.27, 121.37, 106.11, 51.00,
32.06, 31.17, 29.82, 29.79, 29.68, 29.49, 29.08, 22.83, 14.26; Purity:
96.07%; HRMS (ESIþ):m/z calcd for C19H33NO2S [MþH]þ: 340.2304,
found 340.2309.
5.1.2.26. Methyl 2-amino-5-tetradecylthiophene-3-carboxylate
(3aa). Off-solid (94%, 665 mg); m. p. 45e46 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.79 (s, 2H), 3.78 (s, 3H), 2.56 (t,
J ¼ 7.4 Hz, 2H), 1.62e1.50 (m, 2H), 1.35e1.21 (s, 22H), 0.89 (t,
J ¼ 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.88, 161.48, 127.24,
121.35, 106.08, 51.00, 32.06, 31.16, 29.82, 29.68, 29.50, 29.08, 22.83,
14.26; Purity: 97.23%; HRMS (ESIþ): m/z calcd for C20H35NO2S
[MþH]þ: 354.2461, found 354.2461.
5.1.2.27. Methyl (Z)-2-amino-5-(tetradec-9-en-1-yl)thiophene-3-
carboxylate (3ab). Off-white solid (90%, 633 mg); m. p. 32e33 C;
1H NMR (300 MHz, CDCl3) d 6.60 (s, 1H), 5.83 (s, 2H), 5.65e5.10 (m,
2H), 3.78 (s, 3H), 2.56 (t, J ¼ 7.4 Hz, 2H), 2.10e1.94 (m, 4H),
1.64e1.52 (m, 2H), 1.44e1.20 (m, 14H), 0.90 (t, J ¼ 4.9 Hz, 3H); 13C
NMR (151 MHz, CDCl3) d 165.86, 161.50, 129.99, 129.89, 127.14,
121.33, 106.00, 50.98, 32.07, 31.13, 29.85, 29.80, 29.53, 29.43, 29.37,29.04, 27.29, 27.03, 22.46, 14.13; Purity: 96.48%; HRMS (ESIþ): m/z
calcd for C20H33NO2S [MþH]þ: 352.2304, found 270.1523.
5.1.2.28. Methyl 2-amino-5-pentadecylthiophene-3-carboxylate
(3ac). Off-white solid (91%, 667 mg); m. p. 55e56 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.79 (s, 2H), 3.78 (s, 3H), 2.56 (t,
J ¼ 7.3 Hz, 3H), 1.60e1.48 (m, 2H), 1.37e1.19 (s, 24H), 0.88 (t,
J ¼ 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.89, 161.49, 127.25,
121.36, 106.09, 51.00, 32.06, 31.17, 29.83, 29.80, 29.68, 29.50, 29.09,
22.83,14.26; Purity: 96.91%; HRMS (ESIþ):m/z calcd for C21H37NO2S
[MþH]þ: 368.2617, found 368.2614.
5.1.2.29. Methyl 2-amino-5-hexadecylthiophene-3-carboxylate
(3ad). Off-white solid (94%, 718 mg); m. p. 60e61 C; 1H NMR
(300 MHz, CDCl3) d 6.60 (s, 1H), 5.80 (s, 2H), 3.78 (s, 3H), 2.56 (t,
J ¼ 7.3 Hz, 2H), 1.61e1.52 (m, 2H), 1.37e1.18 (s, 26H), 0.88 (t,
J ¼ 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.88, 161.50, 127.23,
121.36, 106.08, 50.99, 32.06, 31.16, 29.83, 29.80, 29.68, 29.50, 29.08,
22.83, 14.25; HRMS (ESIþ): m/z calcd for C22H39NO2S [MþH]þ:
382.2774, found 352.2776.
5.1.2.30. Synthesis of methyl 2-amino-5-(7-(1,3-dioxoisoindolin-2-yl)
heptyl)thiophene-3-carboxylate (5). A solution of 4 (1 g, 3.5 mmol),
methyl cyanoacetate (350mg, 3.5 mol) and triethylamine (351mg,
3.5 mmol) in MeOH (40 ml) was heated at reﬂux temperature for
12 h under argon atmosphere. The MeOH was evaporated under
reduced pressure and the residue was extracted with dichloro-
methane (3  50ml). The combined organic phases were washed
with a saturated solution of NaHCO3, dried over magnesium sulfate
and the solvent was evaporated under reduced pressure. Puriﬁca-
tion by column chromatography (silica, eluent CH2Cl2) afforded 5 as
a pale yellow solid. White solid (84%, 1.19 g); m. p. 60e61 C; 1H
NMR (400MHz, CDCl3) d 7.94e7.77 (m, 2H), 7.76e7.64 (m, 2H), 6.59
(s, 1H), 5.81 (s, 2H), 3.78 (s, 3H), 3.67 (t, J ¼ 7.3 Hz, 2H), 2.62e2.50
(m, 2H), 1.67 (dd, J ¼ 13.7, 7.5 Hz, 2H), 1.56 (dd, J ¼ 14.1, 7.0 Hz, 2H),
1.34 (s, 6H); 13C NMR (101 MHz, CDCl3) d 168.60, 165.85, 161.52,
133.97, 132.29, 127.00, 123.28, 121.44, 106.06, 50.97, 38.13, 30.97,
29.72, 28.97, 28.80, 28.66, 26.82. HRMS (ESIþ): m/z calcd for
C21H24N2O4S [MþH]þ: 401.1529, found 401.1533.
5.1.2.31. Synthesis of methyl 2-amino-5-(7-aminoheptyl)thiophene-
3-carboxylate (6). To a stirred suspension of the compound 5 (1 g,
2.5 mmol), in 30 ml EtOH, hydrazine hydrate (1.5 equiv) was added.
The reaction mixture was then reﬂuxed for 3 h. After this, the re-
action mixture was cooled to room temperature and keep aside for
another 3 h. The resulting precipitatewas ﬁltered off and the ﬁltrate
was evaporated to dryness afforded the corresponding product 6 as
a semi-solid. Semi-solid (63%, 1.19 g); 1H NMR (400 MHz, CDCl3)
d 7.94e7.77 (m, 2H), 7.76e7.64 (m, 2H), 6.59 (s, 1H), 5.81 (s, 2H),
3.78 (s, 3H), 3.67 (t, J ¼ 7.3 Hz, 2H), 2.62e2.50 (m, 2H), 1.67 (dd,
J ¼ 13.7, 7.5 Hz, 2H), 1.56 (dd, J ¼ 14.1, 7.0 Hz, 2H), 1.34 (s, 6H); 13C
NMR (101 MHz, CDCl3) d 168.60, 165.85, 161.52, 133.97, 132.29,
127.00, 123.28, 121.44, 106.06, 50.97, 38.13, 30.97, 29.72, 28.97,
28.80, 28.66, 26.82; purity: 96.60%; HRMS (ESIþ): m/z calcd for
C13H22N2O2S [MþH]þ: 271.1474, found 271.1479.
5.1.2.32. General procedure for the synthesis of 10. To a mixture of 8
(300 mg, 0.79 mmol) and K2CO3 (0.79 mmol) in THF (10 ml) was
added corresponding alky thiol 7 (0.79 mmol). After stirring the
resulting mixture for another 24 h at 45 C, the reaction mixture
was added to water (30 ml). CH2Cl2 (30 ml) was added and the
organic solution was washed with distilled water (3  30 ml) and
then evaporated to dryness to afford the crude product mixture of
9. This crude reaction mixture was then again dissolved in 10 ml of
EtOH and hydrazine (1.2mmol) was then added into it. The reaction
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organic solutionwas washed with distilled water (3 30 ml), dried
over MgSO4, ﬁltered, and then evaporated to dryness to afford the
crude product mixture. Puriﬁcation by column chromatography
(silica, eluent CH2Cl2) afforded corresponding product 10 as a semi-
solid.
5.1.2.33. Methyl 2-amino-5-((butylthio)methyl)thiophene-3-
carboxylate (10a). Semi-solid (33%, 68 mg); 1H NMR (300 MHz,
CDCl3) d 6.75 (s, 1H), 5.93 (s, 2H), 3.79 (s, 3H), 3.68 (s, 2H), 2.46 (t,
J ¼ 7.3 Hz, 2H), 1.68e1.48 (m, 2H), 1.44e1.28 (m, 2H), 0.90 (t,
J ¼ 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 165.70, 162.77, 123.90,
123.84, 105.55, 51.06, 31.25, 31.09, 30.93, 22.08, 13.79; Purity:
95.44%; HRMS (ESIþ): m/z calcd for C11H17NO2S2 [MþH]þ:
260.07734, found 260.07739.
5.1.2.34. Methyl 2-amino-5-((pentylthio)methyl)thiophene-3-
carboxylate (10b). Semi-solid (39%, 83 mg); 1H NMR (300 MHz,
CDCl3) d 6.75 (s, 1H), 5.93 (s, 2H), 3.79 (s, 3H), 3.69 (s, 2H), 2.45 (t,
J ¼ 7.4 Hz, 2H), 1.61e1.50 (m, 2H), 1.39e1.23 (m, 4H), 0.89 (t,
J ¼ 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.73, 162.77, 123.92,
123.87, 105.58, 51.08, 31.24, 31.15, 31.11, 28.86, 22.41, 14.08; Purity:
95.365; HRMS (ESIþ): m/z calcd for C12H19NO2S2 [MþH]þ:
274.0929, found 274.0921.
5.1.2.35. Methyl 2-amino-5-((isopentylthio)methyl)thiophene-3-
carboxylate (10c). Semi-solid (36%, 78 mg); 1H NMR (300 MHz,
CDCl3) d 6.76 (s, 1H), 5.91 (s, 2H), 3.79 (s, 3H), 3.69 (s, 2H), 2.45 (t,
J ¼ 7.8 Hz, 2H), 1.71e1.58 (m, 1H), 1.48e1.39 (m, 2H), 0.88 (t,
J ¼ 6.6 Hz, 6H); 13C NMR (75 MHz, CDCl3) d 165.74, 162.75, 123.96,
123.84, 105.61, 51.10, 38.17, 31.08, 29.27, 27.55, 22.42; Purity:
99.18%; HRMS (ESIþ):m/z calcd for C12H19NO2S2 [MþH]þ: 274.0929,
found 274.0935.
5.1.2.36. Methyl 2-amino-5-((hexylthio)methyl)thiophene-3-
carboxylate (10d). Off-white solid (43%, 97 mg); m. p. 71e72 C;
1H NMR (300 MHz, CDCl3) d 6.75 (s, 1H), 5.91 (s, 2H), 3.77 (s, 3H),
3.69 (s, 2H), 2.46 (t, J ¼ 7.3 Hz, 2H), 1.74e1.48 (m, 2H), 1.41e1.20 (m,
6H), 0.88 (t, J ¼ 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 165.75,
162.75, 123.97, 105.72, 51.08, 31.56, 31.34, 31.16, 29.20, 28.67, 22.68,
14.15; Purity: 95.33%; HRMS (ESIþ): m/z calcd for C13H21NO2S2
[MþH]þ: 288.1086, found 288.1088.
5.1.2.37. Methyl 2-amino-5-((heptylthio)methyl)thiophene-3-
carboxylate (10e). Off-white solid (39%, 93 mg); m. p. 110e111 C;
1H NMR (300 MHz, CDCl3) d 6.75 (s, 1H), 5.93 (s, 2H), 3.79 (s, 3H),
3.68 (s, 2H), 2.45 (t, J¼ 7.3 Hz, 2H), 1.62e1.54 (m, 2H), 1.39e1.23 (m,
8H), 0.87 (t, J ¼ 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 165.72,
162.78, 123.92, 123.87, 105.56, 51.07, 31.83, 31.24, 31.10, 29.17, 28.99,
28.93, 22.72, 14.19; Purity: 97.12%; HRMS (ESIþ): m/z calcd for
C14H23NO2S2 [MþH]þ: 302.1243, found 302.1249.
5.1.2.38. Methyl 2-amino-5-((octylthio)methyl)thiophene-3-
carboxylate (10f). Off-white solid (47%, 117 mg); m. p. 116e117 C;
1H NMR (600 MHz, CDCl3) d 6.75 (s, 1H), 5.92 (s, 2H), 3.79 (s, 3H),
3.69 (s, 2H), 2.45 (t, J ¼ 7.4 Hz, 2H), 1.59e1.52 (m, 2H), 1.31e1.21 (m,
10H), 0.88 (t, J ¼ 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 165.73,
162.75, 123.95, 105.69, 51.07, 31.95, 31.34, 31.16, 29.31, 29.23, 29.00,
22.79, 14.23; Purity: 96.11%; HRMS (ESIþ): m/z calcd for
C15H25NO2S2 [MþH]þ: 316.1399, found 316.1391.
5.1.2.39. Methyl 2-amino-5-((decylthio)methyl)thiophene-3-
carboxylate (10g). Off-white solid (49%, 133 mg); m. p.
106e107 C; 1H NMR (300 MHz, CDCl3) d 6.75 (s, 1H), 5.91 (s, 2H),
3.79 (s, 3H), 3.68 (s, 2H), 2.45 (t, J ¼ 7.3 Hz, 2H), 1.62e1.48 (m, 2H),1.38e1.22 (m, 14H), 0.87 (t, J ¼ 6.4 Hz, 3H); 13C NMR (75 MHz,
CDCl3) d 165.73, 162.77, 123.92, 123.89, 105.58, 51.08, 32.02, 31.25,
31.10, 29.68, 29.65, 29.44, 29.35, 29.18, 28.99, 22.81, 14.25; Purity:
97.39%; HRMS (ESIþ):m/z calcd for C17H29NO2S2 [MþH]þ: 344.1712,
found 344.1718.
5.1.2.40. General procedure for the synthesis of bis-methyl 2-amino-
5-alkylthiophene-3-carboxylate derivatives 12. as shown in Table 3.
A solution of bis-aliphatic aldehyde 11 (1 mmol), activated nitrile
(2 mmol), elemental sulfur (2 mmol) and triethylamine (2mmol) in
MeOH (15 ml) was heated at reﬂux temperature for 16 h under
argon atmosphere. The MeOH was evaporated under reduced
pressure and the residue was extracted with dichloromethane
(3  30 ml). The combined organic phases were washed with a
saturated solution of NaHCO3, dried over magnesium sulfate and
the solvent was evaporated under reduced pressure. Puriﬁcation by
column chromatography (silica, eluent CH2Cl2) afforded 12 as an
off-white solid.
5.1.2.41. Dimethyl 5,5'-(ethane-1,2-diyl)bis(2-aminothiophene-3-
carboxylate) (12a). Off-white solid (33%, 107 mg); m. p. 53e51 C;
1H NMR (300 MHz, CDCl3) d 6.58 (s, 2H), 5.75 (s, 4H), 3.71 (s, 6H),
2.78 (s, 4H); 13C NMR (75 MHz, CDCl3) d 165.84, 161.76, 124.78,
122.51, 106.16, 51.07, 31.48; Purity: 96.81%; HRMS (ESIþ): m/z calcd
for C14H16N2O4S2 [MþH]þ: 341.0624, found 341.0629.
5.1.2.42. Dimethyl 5,5'-(butane-1,4-diyl)bis(2-aminothiophene-3-
carboxylate) (12b). Off-white solid (42%, 143 mg); m. p. 51e52 C;
1H NMR (300 MHz, CDCl3) d 6.60 (s, 2H), 3.78 (s, 6H), 2.58 (sbr, 4H),
1.61 (sbr, 4H); 13C NMR (75 MHz, CDCl3) d 165.83, 161.57, 126.46,
121.66, 106.06, 51.02, 30.26, 29.49; Purity: 95.344%; HRMS (ESIþ):
m/z calcd for C16H20N2O4S2 [MþH]þ: 369.0931, found 369.0929.
5.1.2.43. Dimethyl 5,5'-(pentane-1,5-diyl)bis(2-aminothiophene-3-
carboxylate) (12c). Off-white solid (53%, 195 mg); m. p. 45e46 C;
1H NMR (3 00 MHz, CDCl3) d 6.60 (s, 2H), 5.80 (s, 4H), 3.79 (s, 6H),
2.62e2.48 (m, 4H), 1.68e1.51 (m, 4H), 1.44e1.18 (m, 2H); 13C NMR
(75 MHz, CDCl3) d 165.85, 161.51, 126.83, 121.55, 106.11, 51.02, 30.81,
29.66, 28.23; Purity: 99.12%; HRMS (ESIþ): m/z calcd for
C17H22N2O4S2 [MþH]þ: 383.1093, found 383.1095.
5.1.2.44. Dimethyl 5,5'-(octane-1,8-diyl)bis(2-aminothiophene-3-
carboxylate) (12d). Off-white solid (44%, 187 mg); m. p.
59e60 C; 1HNMR (400MHz, CDCl3) d 6.60 (s, 2H), 5.83 (s, 4H), 3.78
(s, 6H), 2.55 (t, J ¼ 7.5 Hz, 4H), 1.54 (dd, J ¼ 14.3, 7.1 Hz, 4H), 1.29 (s,
8H); 13C NMR (101 MHz, CDCl3) d 165.84, 161.53, 127.07, 121.37,
106.00, 50.97, 31.04, 29.75, 29.26, 28.91; Purity: 97.41%; HRMS
(ESIþ): m/z calcd for C20H28N2O4S2 [MþH]þ: 425.1563, found
425.1561.
5.1.2.45. General procedure for the synthesis of 2-amino-5-(alkynyl)
thiophene-3-carboxylate derivatives 14. PdCl2(PPh3)2 (0.05 mmol),
CuI (0.1 mmol), and 13 (366 mg, 1.0 mmol) were added to an oven-
dried two-neck ﬂask. The ﬂask was evacuated and backﬁlled with
argon (3 cycles) and then charged with THF (10.0 mL). The solution
was stirred for 30 min at room temperature. Then the corre-
sponding alkyne (1.5 mmol) and NEt3 (3 mmol) were added by
syringe. The reaction mixture was heated to 50 C and stirred for
24 h. The reaction mixture was then allowed to reach room tem-
perature. CH2Cl2 (20 ml) was added and the organic solution was
washed with distilled water (3  20 ml) and then evaporated to
dryness to afford the crude intermediate. Inorganic byproducts
after this reaction were then removed by ﬂash chromatography
(silica, eluent CH2Cl2). This crude reaction mixture was then again
dissolved in 10 ml of EtOH and hydrazine (1 equiv) was then added
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was added and the organic solution was washed with distilled
water (3  30 ml), dried over MgSO4, ﬁltered, and then evaporated
to dryness to afford the crude product mixture. Puriﬁcation by
column chromatography (silica, eluent CH2Cl2) afforded the cor-
responding product (14a or 14b) as an off-white solid.
5.1.2.46. Methyl 2-amino-5-(hept-1-yn-1-yl)thiophene-3-
carboxylate (14a). Off-white solid (29%, 73 mg); m. p. 48e49 C;
1H NMR (400 MHz, CDCl3) d 6.99 (s, 1H), 5.97 (s, 2H), 3.78 (s, 3H),
2.36 (t, J ¼ 7.1 Hz, 2H), 1.56 (dt, J ¼ 14.6, 7.1 Hz, 2H), 1.44e1.16 (m,
4H), 0.90 (t, J ¼ 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 165.48,
162.45, 129.97, 106.25, 105.82, 92.93, 73.51, 51.23, 31.24, 28.48,
22.35, 19.76, 14.11; Purity: 97.79%; HRMS (ESIþ): m/z calcd for
C13H17NO2S [MþH]þ: 252.1052, found 252.1056.
5.1.2.47. Methyl 2-amino-5-((4-hexylphenyl)ethynyl)thiophene-3-
carboxylate (14b). Off-white solid (47%, 160 mg); m. p. 45e46 C;
1H NMR (400 MHz, CDCl3) d 7.36 (d, J ¼ 8.1 Hz, 2H), 7.16 (s, 1H), 7.13
(d, J ¼ 8.1 Hz, 2H), 6.13 (s, 2H), 3.81 (s, 3H), 2.59 (t, 2H), 1.59 (dd,
J ¼ 14.2, 7.2 Hz, 2H), 1.28 (t, J ¼ 8.3 Hz, 6H), 0.88 (t, J ¼ 6.6 Hz, 3H);
13C NMR (101 MHz, CDCl3) d 165.46, 163.22, 143.53, 131.32, 131.07,
128.60, 120.27, 106.66, 105.00, 91.78, 82.08, 51.31, 36.05, 31.83,
31.33, 29.05, 22.73, 14.22; Purity: 96.95%; HRMS (ESIþ): m/z calcd
for C20H23NO2S [MþH]þ: 342.1522, found 342.1527.
5.1.2.48. Synthesis of methyl 2-amino-5-(octylthio)thiophene-3-
carboxylate (15). (Pd2(dba)3) (0.01 mmol), 1,10-Ferrocenediyl-bis(-
diphenylphosphine), (DPPF), (0.02 mmol) and 13 (192 mg,
0.53 mmol) were added to an oven-dried two-neck ﬂask. The ﬂask
was evacuated and reﬁlled with argon (3 cycles) and then charged
with toluene (6.0 ml). The solution was stirred for 1 h at room
temperature. Then the 1-octanethiol (78 mg, 0.53 mmol) and
iPr2NEt (0.58 mmol) were added by syringe. The reaction mixture
was heated to 100 C and stirred for 3 h. The reaction mixture was
then allowed to reach room temperature. CH2Cl2 (30ml) was added
and the organic solution was washed with distilled water
(3  20 ml) and then evaporated to dryness to afford the crude
intermediate. Inorganic byproducts were then removed by ﬂash
chromatography (silica, eluent CH2Cl2). This crude reactionmixture
was then again dissolved in 5 ml of EtOH and hydrazine (1 equiv)
was then added into it. The reaction mixture was reﬂuxed for 3 h.
CH2Cl2 (30 mL) was added and the organic solution was washed
with distilled water (3  20 mL), dried over MgSO4, ﬁltered, and
then evaporated to dryness to afford the crude product mixture.
Puriﬁcation by column chromatography (silica, eluent CH2Cl2)
afforded corresponding product as a semi-solid. Off-white solid
(59%, 94 mg); m. p. 36e37 C; 1H NMR (300 MHz, CDCl3) d 7.05 (s,
1H), 6.04 (s, 2H), 3.80 (s, 3H), 2.65 (t, J ¼ 7.4 Hz, 2H), 1.64e1.52 (m,
2H),1.31 (d, J¼ 29.3 Hz,10H), 0.88 (s, 3H); 13C NMR (75MHz, CDCl3)
d 165.43, 134.07, 115.31, 107.06, 51.22, 38.88, 31.94, 29.43, 29.31,
29.26, 28.52, 22.78, 14.24; Purity: 99.21%; HRMS (ESIþ): m/z calcd
for C14H23NO2S2 [MþH]þ: 302.1248, found 302.1241.
5.1.2.49. Synthesis of methyl 2-amino-5-(7-((5-(dimethylamino)
naphthalene)-1-sulfonamido)heptyl)thiophene-3-carboxylate (17).
A solution of 6 (0.150 mg, 0.15 mmol), dansyl chloride 16 (149,
0.15 mol) and triethylamine (15 mg, 0.15 mmol) in DMF (2 ml) was
treated at room temperature for 8 h under argon atmosphere. The
DMF was evaporated under reduced pressure and the residue was
extracted with EtOAc (3  10ml). The combined organic phases
were washed with a saturated solution of NaHCO3, dried over
magnesium sulfate and the solvent was evaporated under reduced
pressure. Puriﬁcation by column chromatography (silica, eluent
CH2Cl2) afforded 17 as a red solid. Red solid (71%, 60 mg); m. p.44e45 C; 1H NMR (300 MHz, CDCl3) d 8.58 (d, J ¼ 8.9 Hz, 1H),
8.33e8.26 (m, 2H), 7.64e7.41 (m, 2H), 7.20 (d, J ¼ 6.0 Hz, 1H), 6.24
(s, 1H), 5.79 (s, 2H), 4.71 (t, J ¼ 6.0 Hz, 1H), 3.81 (s, 3H), 3.04e2.99
(m, 2H), 2.93 (s, 6H), 2.57 (t, J ¼ 7.4 Hz, 2H), 1.75e1.40 (m, 4H),
1.44e1.16 (m, 6H); 13C NMR (101 MHz, CDCl3) 165.8, 161.6, 152.9,
135.6, 131.4, 130.8, 130.7, 130.6, 129.4, 127.3, 121.4, 124.2, 119.7, 116.1,
106.1, 50.2, 46.4, 39.3, 32.0, 31.2, 29.9, 29.2, 29.1, 29.0, 28.9; Purity:
98.43%; (ESIþ): m/z calcd for C25H33N3O4S2 [MþH]þ: 504.1985,
found 504.1981.
5.1.2.50. Synthesis of methyl 2-amino-5-(7-((7-nitrobenzo[c][1,2,5]
oxadiazol-4-yl)amino)heptyl)thiophene-3-carboxylate (19). A solu-
tion of 6 (200 mg, 0.75 mmol), 4-chloro-7-nitrobenzofurazan 18
(146 mg, 0.75 mol) and N,N-diisopropylethylamine (97 mg,
0.75mmol) in DMF (5ml) was treated at room temperature for 24 h
under argon atmosphere. The DMF was evaporated under reduced
pressure and the residue was extracted with EtOAc (3  50ml). The
combined organic phases were washed with a saturated solution of
NaHCO3, dried over magnesium sulfate and the solvent was evap-
orated under reduced pressure. Puriﬁcation by column chroma-
tography (silica, eluent CH2Cl2) afforded 19 as a red solid. Red solid
(59%, 192 mg); m. p. 44e45 C; IR (ATR): 3462, 3351, 3281, 2930,
2851, 1676, 1580, 1398, 1314, 1296, 1186, 1120, 998, 775; 1H NMR
(300 MHz, CDCl3) d 8.53 (d, J ¼ 8.6 Hz, 1H), 6.63 (s, 1H), 6.26 (s, 1H),
6.19 (d, J ¼ 8.7 Hz, 1H), 5.81 (s, 2H), 3.81 (s, 3H), 3.51 (dd, J ¼ 13.0,
6.9 Hz, 2H), 2.60 (t, J ¼ 7.0 Hz, 2H), 1.86e1.77 (m, 2H), 1.62 (s, 4H),
1.46 (dd, J ¼ 13.8, 8.1 Hz, 4H); 13C NMR (101 MHz, CDCl3) d 165.78,
161.45, 144.39, 144.03, 136.66, 126.75, 124.04, 121.61, 106.12, 98.66,
51.04, 44.09, 30.87, 29.69, 28.99, 28.70, 28.60, 26.90; Purity: 99.89%;
HRMS (ESIþ): m/z calcd for C19H23N5O5S [MþH]þ: 434.1495, found
434.1493.
5.2. Biology
5.2.1. Tumor cells
Following tumor cell lines were included in the anti-
proliferative assays: human T-lymphoma CEM and Molt/4 cells, B-
lymphoma Raji cells and solid prostate PC-3, kidney Caki-1, liver
Huh-7 hepatoma and cervix carcinoma HeLa tumor cells.
The NCI-60 cancer cell line panel consisted of the following
well-deﬁned and characterized tumor cell lines: leukemia/lym-
phoma: CCRF-CEM, Molt-4, HL-60, RPMI-P226, K-562, SR; central
nervous system (CNS): SF-268, SNB-19, SF-295, SNB-75, SF-539,
U251; colon: Colo205; HCT-15, SW-620, HCC-2998, HT29, HCT-
116, KM12; non-small cell lung: A549/ATCC, NCI-H322 M, H0P-
62, NCI-H460, NCI-H225, NCI-H522; melanoma: LOX IMVI, SK-
HEL-2, UACC-257, M14, SK-MEL-28, UACC-62, MDA-MB-435, SK-
MEL5; prostate: PC-3, DU-145; renal: 786-D, CAKI-1, UO-31, A4989,
RXF393, ACHN, SN12C; breast: MCF47, BT-549, MDA-MB-231, MDA-
MB-468, HS 578T; ovarian: IGROVI, OVCAR-5, SK-OV-3, OVCAR-3,
OVCAR-8, OVCAR-4, NCI/ADR-RES.
5.2.2. Anti-proliferation assays
Cells (5e7.5  104 cells) and a serial (5-fold) dilution of the test
compounds were added to a 96-well microtiter plate. The cells
were allowed to proliferate for 72 he96 h (depending on the nature
of the tumor cell line) at 37 C in a humidiﬁed CO2-controlled at-
mosphere. At the end of the incubation period, the cells were
counted in a Coulter Counter (Coulter Electronics Ltd, Harpenden
Herts, United Kingdom). The IC50 (50% inhibitory concentration)
was deﬁned as the concentration of compound that inhibited the
proliferation of the tumor cells by 50%. The IC50 values represent
the average (±standard deviation) of at least 2 to 4 independent
experiments.
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PC-3 cells were seeded as described previously and allowed to
adhere overnight at 37 C. Next, the cells were exposed to different
concentrations (0e50 mM) of 3j for 1 h, 4 h, 24 h and 48 h after
which they were rinsed twice with DMEM (37 C) and further
cultured in drug-free DMEM. Alternatively, the drug was left on the
cell cultures until the cells were harvested and counted at 72 h after
the start of drug treatment (control experiment). The experiments
were performed in duplicate.
5.2.4. Daily pulse-treatments of PC-3 cell cultures by 3j
PC-3 cells were seeded into 96-well plates at 10,000 cells/well
and allowed to adhere overnight at 37 C. For drug treatment the
culture supernatants were replaced by pre-warmed (37 C) me-
dium containing 0, 0.4, 2 or 10 mM 3j in duplicates and left for 1e4 h
followed by removal of the drug, rinsing with DMEM (37 C) and
addition of fresh DMEM (37 C). Treatment was repeated every day
for 4 subsequent days and the cells were harvested and counted on
the ﬁfth day. In a control experiment, the various drug concentra-
tions were left on the tumor cell cultures for the entire duration of
the experiment. The experiments were performed in duplicate.
5.2.5. Drug resistance development through prolonged escalating
drug administrations selection of PC-3- and CEM-resistant cells was
performed by treatment of the tumor cell cultures with increasing
concentrations of TR560 or 3j
Therefore, cells were initially treated with 100 nM of either
drug. Next, the cultures were subcultured (passaged) every 4 or 5
days. At every passage, fresh drug was added and the concentration
gradually increased according to the morphological state and
growth of the respective cell cultures, as monitored by light mi-
croscopy. At the end of the selection procedure, the tumor cells
were maintained for at least ﬁve more subcultivations in the
presence of the highest drug concentration used (10 mM).
5.2.6. Intracellular drug localization imaging
PC-3 cells were seeded into 8-well chamber slides at a density of
20.000e60,000 cells/well and allowed to adhere for 24e48 h at
37 C. The cells were thereafter transduced with 50 baculovirus
particles/cell using the CellLight®Reagents*BacMam 2.0* kit (Mo-
lecular Probes by Life technologies) to express RFP in various
intracellular organelles for 16e24 h. The supernatants were sub-
sequently discarded, the cells rinsed twice with phenol red-free
DMEM (37 C) (Life technologies) and 10 mM of NBD-labeled 3j
(19), prepared in phenol-red free DMEM, was added immediately
prior to monitoring the ﬂuorescence-derived RFP and 19 by
confocal ﬂuorescence microscopy.
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